Preoperative hysteroscopy shortened progression-free survival in advanced FIGO stage in endometrial cancer: Ten year analysis

被引:1
作者
Miao, Huixian [1 ]
Zhang, Lin [1 ]
Jiang, Yi [1 ]
Wan, Yicong [1 ]
Yuan, Lin [1 ]
Cheng, Wenjun [1 ,2 ]
机构
[1] Nanjing Med Univ, Jiangsu Prov Hosp, Dept Gynecol, Affiliated Hosp 1, Nanjing, Peoples R China
[2] Nanjing Med Univ, Dept Gynecol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
advanced FIGO stage; dilation and curettage; endometrial carcinoma; hysteroscopy; prognosis; recurrence; survival; CARCINOMA; PROGNOSIS; CYTOLOGY; CELLS;
D O I
10.1002/ijgo.15180
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To investigate the impact of preoperative hysteroscopy on progression-free survival (PFS) and disease-specific survival (DFS), and to explore the factors which contribute to poor clinical outcomes between hysteroscopy and dilation and curettage (D&C) in endometrial cancer (EC).Methods: A retrospective study was designed by collecting data from women diagnosed with EC through hysteroscopy or D&C from January 2010 to December 2019 in a tertiary hospital in China. A propensity score was used for 1:1 matching of advanced stage patients. Univariate and multivariate analysis were conducted to determine whether hysteroscopy was a prognostic factor in EC and to identify factors associated with its impact on PFS and DFS in different subgroups.Results: Overall, 543 and 272 women who underwent D&C and hysteroscopy, respectively were included. Compared to D&C, preoperative hysteroscopy was related to reduced PFS and DFS, with a hazard ratio (HR) of 1.904 and 3.905, respectively. Hysteroscopy contributed to an increased risk of positive wash cytology (48.27% vs 24.13%), recurrence (48.28% vs 20.69%) and shorter PFS after matching in FIGO Stage I-IV EC, while there was no significance in positive ascites cytology (14.04% vs 13.45%), PFS and DFS in FIGO Stage I EC.Conclusions: Hysteroscopy was an independent predictive factor for poor prognosis in EC. Hysteroscopy appeared to be a safe diagnostic method as D&C in FIGO Stage I EC but was a risk factor for increased recurrence and reduced PFS in advanced stage disease. Its impact on DFS is uncertain.
引用
收藏
页码:1195 / 1204
页数:10
相关论文
共 50 条
[21]   Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country [J].
Radojevic, Marija Zivkovic ;
Mujkovic, Srdan ;
Zoran, Protrka ;
Loncar, Dragan ;
Nedovic, Nikola ;
Nedovic, Jasmina ;
Vojinovic, Radisa ;
Dimitrijevic, Aleksandra ;
Vulovic, Tatjana ;
Milosavljevic, Neda .
JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2023, 15 (05) :297-307
[22]   Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib [J].
Badaoui, Sarah ;
Kichenadasse, Ganessan ;
Rowland, Andrew ;
Sorich, Michael J. ;
Hopkins, Ashley M. .
ONCOLOGIST, 2021, 26 (07) :562-568
[23]   Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival [J].
Coada, Camelia Alexandra ;
Dondi, Giulia ;
Ravegnini, Gloria ;
Di Costanzo, Stella ;
Tesei, Marco ;
Fiuzzi, Enrico ;
Di Stanislao, Marco ;
Giunchi, Susanna ;
Zamagni, Claudio ;
Bovicelli, Alessandro ;
Hrelia, Patrizia ;
Angelini, Sabrina ;
De Iaco, Pierandrea ;
Perrone, Anna Myriam .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (06)
[24]   Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer? [J].
Bilici, Ahmet ;
Ustaalioglu, Bala Basak Oven ;
Ercan, Serif ;
Orcun, Asuman ;
Seker, Mesut ;
Salepci, Taflan ;
Gumus, Mahmut .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (02) :309-316
[25]   Ovarian cancer Stage IIIC. Consequences of treatment level on overall and progression-free survival [J].
Oksefjell, H. ;
Sandstad, B. ;
Trope, C. .
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2006, 27 (03) :209-214
[26]   The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation [J].
Tizianel, Irene ;
Caccese, Mario ;
Torresan, Francesca ;
Lombardi, Giuseppe ;
Evangelista, Laura ;
Crimi, Filippo ;
Sepulcri, Matteo ;
Iacobone, Maurizio ;
Padovan, Marta ;
Galuppini, Francesca ;
Zagonel, Vittorina ;
Scaroni, Carla ;
Ceccato, Filippo .
CANCERS, 2022, 14 (16)
[27]   Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer [J].
Mou, Zhuofan ;
Spencer, Jack ;
Knight, Bridget ;
John, Joseph ;
McCullagh, Paul ;
McGrath, John S. ;
Harries, Lorna W. .
FRONTIERS IN ONCOLOGY, 2022, 12
[28]   Consolidation chemotherapy improves progression-free survival in stage III small-cell lung cancer following concurrent chemoradiotherapy: a retrospective study [J].
Chen, Xin-Ru ;
Liang, Jian-Zhong ;
Ma, Shu-Xiang ;
Fang, Wen-Feng ;
Zhou, Ning-Ning ;
Liao, Hai ;
Li, De-Lan ;
Chen, Li-Kun .
ONCOTARGETS AND THERAPY, 2016, 9 :5729-5736
[29]   Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development [J].
Barber, Paul R. ;
Mustapha, Rami ;
Flores-Borja, Fabian ;
Alfano, Giovanna ;
Ng, Kenrick ;
Weitsman, Gregory ;
Dolcetti, Luigi ;
Mohamed, Ali Abdulnabi ;
Wong, Felix ;
Vicencio, Jose M. ;
Galazi, Myria ;
Opzoomer, James W. ;
Arnold, James N. ;
Thavaraj, Selvam ;
Kordasti, Shahram ;
Doyle, Jana ;
Greenberg, Jon ;
Dillon, Magnus T. ;
Harrington, Kevin J. ;
Forster, Martin ;
Coolen, Anthony C. C. ;
Ng, Tony .
ELIFE, 2022, 11
[30]   Three-year interim results of overall and progression-free survival in a cohort of patients with prostate cancer (GESCAP group) [J].
Cozar, J. M. ;
Minana, B. ;
Gomez-Veiga, F. ;
Rodriguez-Antolin, A. .
ACTAS UROLOGICAS ESPANOLAS, 2019, 43 (01) :4-11